Aeon is developing precision missile systems, including anti-tank guided missiles and precision glide munitions, using advanced defense software and hardware to enhance military capabilities. The company aims to provide cost-effective solutions that ensure superior operational effectiveness for the US and its allies.

Affect Therapeutics offers a smartphone app that integrates contingency management with virtual therapy to support individuals recovering from drug and alcohol addiction. The platform provides financial incentives for healthy behaviors, along with personalized care and resources to facilitate lasting lifestyle changes.

Allen Control Systems develops autonomous weapon stations for land and sea defense applications. These systems utilize passive sensing technology for covert operation against Group 1-3 UAS threats, integrating with existing command and control architectures. The product line offers various configurations supporting kinetic and less-than-lethal countermeasures for precision engagement.

Alto Neuroscience develops precision medicines for neuropsychiatric conditions using an AI-driven biomarker platform to predict clinical responses and identify patients most likely to benefit from their drug candidates. Their focus on major depressive disorder, bipolar depression, and schizophrenia aims to replace the trial-and-error approach in psychiatric treatment with targeted therapies based on deep neurobiological insights.

Alto is a digital pharmacy that utilizes a mobile app to streamline prescription management, offering features such as seamless ordering, delivery scheduling, and direct pharmacist support. This service addresses the inconvenience of traditional pharmacy experiences by providing same-day delivery and easy prescription transfers, ensuring timely access to medications.

Applied Cognition develops therapeutics by targeting the glymphatic system, a mechanism for clearing waste from the brain. The company utilizes a proprietary, non-invasive platform for real-time glymphatic measurement to identify and screen drug candidates. Their pipeline focuses on lead compounds for high-value neurological indications including Alzheimer's and Parkinson's disease.

Aptihealth provides integrated behavioral healthcare through personalized care plans, teletherapy, and medication management, ensuring timely access for individuals aged 5 and older. The platform addresses the significant delays in mental health treatment by offering 24/7 support and direct messaging with therapists, facilitating immediate and effective care coordination.

Atai Life Sciences is a clinical-stage biopharmaceutical company developing novel therapeutics for mental health conditions. They are advancing psychedelic and non-psychedelic compounds, including DMT, MDMA, and psilocin, to offer rapid-acting and durable relief for patients with treatment-resistant depression, social anxiety disorder, and cognitive impairment.

Beckley Psytech is developing a novel synthetic intranasal formulation of 5-MeO-DMT benzoate, designed to provide rapid and lasting treatment effects for mental health conditions such as Treatment Resistant Depression and Alcohol Use Disorder. The company addresses the significant unmet need for effective and accessible mental health treatments by leveraging next-generation psychedelic compounds that can be administered in a short clinic visit.

Bionaut Labs develops microscale robots that utilize magnetic propulsion to navigate complex 3D trajectories within the human body, enabling localized delivery of biologics and small molecule therapies to targeted areas of severe brain disorders. This technology addresses the challenge of accessing deep anatomical regions for precise treatment and diagnostic detection, enhancing safety and efficacy in patient care.